Release Date: September 30, 2025
Expiration Date: September 30, 2026
Activity Overview
Heart failure (HF), a major challenge in cardiovascular medicine, presents significant morbidity and mortality despite advances in treatment. Mineralocorticoid receptor antagonists (MRAs) have emerged as a cornerstone of therapy, demonstrating substantial benefits in reducing hospitalization, improving survival, and enhancing quality of life in appropriately selected patients.
This program is designed to provide physicians with a comprehensive understanding of the role of MRAs in managing HF. Expert faculty will review the underlying pathophysiology of MR activation, discuss clinical evidence supporting both steroidal and nonsteroidal MRAs across the spectrum of HF phenotypes, and highlight practical strategies for patient selection, initiation, monitoring, and long-term management. Through interactive case discussions and evidence-based updates, participants will gain insights into optimizing MRA use in clinical practice, addressing challenges that include hyperkalemia and renal function, and integrating MRAs into guideline-directed medical therapy.
Target Audience
This educational activity is directed toward cardiologists, primary care physicians, nurse practitioners, physician assistants, and registered nurses who specialize in treating patients with HF.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize clinical characteristics of the steroidal and non-steroidal classes of mineralocorticoid receptor antagonists (MRAs)
- Analyze recent clinical trial efficacy and safety data for MRAs studied in patients with HFmrEF and/or HFpEF
- Integrate emerging evidence regarding the use of MRAs into the development of individualized guideline-directed treatment plans for appropriate patients with HFmrEF or HFpEF
Edgar V. Lerma, MD
Clinical Professor of Medicine
University of Illinois at Chicago
Chicago, IL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Astra Zeneca, Bayer, Calliditas, Idorsia, Novo Nordisk, Novartis, Natera, Opko, Otsuka, Travere, Vera, Vertex, Vifor; Royalty or Patent Benefits: Elsevier, McGraw-Hill, Springer, Wolters Kluwer
Anuradha Lala-Trindade, MD
Associate Professor, Department of Cardiology
Advanced Heart Failure & Transplant
The Mount Sinai Hospital
New York, NY
Anuradha Lala-Trindade, MD, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here